Niacin extended release (ER)simvastatin (Simcor®): A guide to its use in lipid regulation

Drugs in R and D

Volumn 10, Issue 4, 2010, Pages 253-260

  Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Hyperlipidaemia, treatment; Niacinsimvastatin, therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; GLUCOSE TOLERANCE; GOUT; HEADACHE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYOPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; NIACIN; SIMVASTATIN;

EID: 79953193063     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11202560-000000000-00000     Document Type: Article

References (23)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul. 13; 110(2):227-39 (Pubitemid 38924592)
2. Cannon CP. Combination therapy in the management of mixed dyslipidemia. J Intern Med 2008 Apr; 263(4):353-65 (Pubitemid 351342686)
3. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007 Jun; 192(2):432-7 (Pubitemid 46726341)
4. ® (simvastatin and niacin tablet, film coated extended release): US prescribing information. North Chicago (IL): Abbott Laboratories, 2010 Jul
5. Insull Jr W, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004 May 24; 164(10):1121-7 (Pubitemid 38668992)
6. Hunninghake DB, McGovern ME, Koren M, et al. A doseranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003 Mar; 26:112-8 (Pubitemid 36330859)
7. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I Study). Am J Cardiol 2008 May 15; 101(10):1428-36
8. Ballantyne CM, Davidson MH, McKenney JM, et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80mg monotherapy: the SEACOAST II (highdose) study. J Clin Lipidol 2008 Apr; 2(2):79-90 (Pubitemid 351372956)
9. Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extendedrelease niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003 Jun. 1; 91(11):1304-10 (Pubitemid 36593473)
10. Insull Jr W, Basile JN, Vo AN, et al. Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: the SUPREME study. J Clin Lipid 2009 Apr; 3(2):109-18
11. Sang ZC, Wang F, Zhou Q, et al. Combined use of extendedrelease niacin and atorvastatin: safety and effects on lipid modification. Chin Med J (Engl) 2009 Jul. 20; 122(14):1615-20
12. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 Dec. 7; 110(23):3512-7 (Pubitemid 39612564)
13. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006 Nov; 22(11):2243-50 (Pubitemid 44789989)
14. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010 Jun. 15; 55(24):2721-6
15. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009 Nov. 3; 54(19):1787-94
16. Frutkin AD, Baas A, O'Brien KD, et al. Reduction in high sensitivity C-reactive protein (hsCRP) during simvastatin and niacin therapy correlates with angiographic change in coronary artery stenosis: results from the HDL atherosclerosis treatment study (HATS) [abstract no. 2689]. Circulation 2003;108(17 Suppl. IV): 590-1
17. Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia. Am J Cardiovasc Drug 2008;8(2):69-81 (Pubitemid 351570857)
18. Bays H. Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008 Apr. 17; 101 (8A): 3-8B
19. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract 2009 Sep; 63(9):1369-77
20. Thakkar RB, Kashyap ML, Lewin AJ, et al. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs 2009;9(2):69-79
21. ©): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Invest 2009;29(4):215-29
22. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007 Mar; 99 (6 Suppl.): S22-31 (Pubitemid 46412228)
23. National Heart, Lung, and Blood Institute (NHLBI). Niacin plus statin to prevent vascular events [ClinicalTrials.gov identifier NCT00120289]. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Oct. 29]